Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mtor suppression and up-regulation and activation of glucocorticoid receptor

Biomedical and Environmental Sciences

Volumn 26, Issue 5, 2013, Pages 371-381

  Xia, Guo ^a   Yan, Zhou Chen ^a   Qiang, Li ^a   Ju, Gao ^a   Ping, Zhu Yi ^a   Ling, Gu ^a   Gui, Ma Zhi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Glucocorticoid receptor; Glucocorticoid resistance; MTOR; Rapamycin

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PRIMER DNA; RAPAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL LINE; DRUG EFFECT; GLUCOCORTICOID RESISTANCE; HUMAN; METABOLISM; MTOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ACUTE LYMPHOBLASTIC LEUKEMIA; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RESISTANCE; MTOR; RAPAMYCIN;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; DEXAMETHASONE; DNA PRIMERS; GLUCOCORTICOIDS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; SIROLIMUS; UP-REGULATION;

MLCS; MLOWN;

EID: 84881260044     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.3967/0895-3988.2013.05.006     Document Type: Article

References (32)

1. Schrappe M, Reter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia, 2000; 14, 2205-22.
2. Greenstein S, Ghias K, Krett NL, et al. Mechanism of glucocorticoid- mediated apoptosis in hematological malignancies. Clin Cancer Res, 2002; 8, 1681-94.
3. Kaspers GJ, Pieters R, Klumper E, et al. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma, 1994; 13, 187-201.
4. Schmidt S, Irving JA, Minto L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J, 2006; 20, 2600-2.
5. Zhou M, Gu L, Findley HW, et al. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res, 2003; 63, 6357-62.
6. Astoul E, Edmunds C, Cantrell DA, et al. PI3K and T cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol, 2001; 22, 490-6.
7. Uddin S, Hussain A, Al-Hussein K, et al. Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun, 2004; 320, 932-8.
8. Montiel-Duare C, Cordeu L, Agirre X, et al. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res, 2008; 32, 709-16.
9. Bornhauser BC, Bonapace L, Lindholm D, et al. Low dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood, 2007; 110, 2084-91.
10. Beesley AH, Firth MJ, Ford J, et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer, 2009; 100, 1926-36.
11. Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol, 2004; 287, C281-91.
12. Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun, 2003; 310, 1124-32.
13. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 2006; 10, 331-42.
14. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood, 1995; 86, 3861-8.
15. Kaspers GJ, Pieters R, Klumper E, et al. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma, 1994; 13, 187-201.
16. Kaspers GJ, Wijnands JJ, Hartmann R, et al. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer, 2005; 41, 1300-3.
17. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol, 2005; 93, 153-60.
18. Kofler R, Schmidt S, Kofler A, et al. Resistance to glucocorticoid- induced apoptosis in lymphoblastic leukemia. J Endocrinol, 2003; 178, 19-27.
19. Sanchez-Vega B, Krett N, Rosen ST, et al. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther, 2006; 5, 3062-70.
20. Geley S, Hartmann BL, Hala M, et al. Resistance to glucocoricoid-induced apoptosis in human T-ALL acute lymphoblastic leukemia CEM-C1 is due to insufficient glucocorticoid receptor expression. Cancer Res, 1996; 56, 5033-8.
21. Webster JC, Oakley RH, Jewell CM, et al. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: A mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. U.S.A, 2001; 98, 6865-70.
22. Charmandari E, Chrousos GP, Ichijo T, et al. The Human glucocorticoid receptor (hGR) isoform suppresses the transcriptional activity of hGR? by interfering with formation of active coactivator complexes. Mol Endocrinol, 2005; 19, 52-64.
23. Tissing WJ, Meijerink JP, den Boer ML, et al. Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res, 2005; 11, 6050-6.
24. Gu L, Gao J, Li Q, et al. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia, 2008; 22, 2091-6.
25. Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood, 2004; 103, 3138-47.
26. Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature, 2003; 426, 671-6.
27. Stam RW, Den Boer ML, Schneider P, et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood, 2010; 115, 1018-25.
28. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med, 2004; 351, 533-42.
29. Zhao YN, Li Q, Yang K. Role of Pro-Apoptotic protein Bim in mouse thymocytes apoptosis induced by dexamethasone. Journal of Sichuan University (Medical Science Edition), 2007; 38, 851-4. (In Chinese)
30. Zhao YN, Guo X, Ma ZG, et al. Pro-Apopototic protein BIM in apoptosis of glucocorticoid-sensitive and-resistant acute lymphoblastic leukemia CEM cells. Med Oncol, 2011; 28, 1609-17.
31. Miller AL, Garza AS, Johnson BH, et al. Pathway interactions between MAPKs, mTOR, PKA, and the gluococorticoid receptor in lymphoid cells. Cancer Cell Int, 2007; 7, 3.
32. Gu L, Zhou CY, Liu HJ, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res, 2010; 29, 150.